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Therapy (PDT) and best supportive care in treating patients
with AMD. METHODS: A cost-effectiveness model was created
using outcome data from the ANCHOR and MARINA clinical
trials. The model operates on quarterly cycles and a 10-year
time horizon. At baseline, Early Treatment Diabetic Retinopa-
thy Study (ETDRS) visual acuity was 55 and average age was
77 in the base case. Cost of services were obtained from the
CMS website, drug costs were obtained from ASP prices, and
visual impairment costs were based on a prospective study by
Schmier and colleagues. All costs were inﬂated to 2007 dollars
using the Health Services CPI. Utility values were based on a
time-tradeoff analysis conducted by Brown and colleagues. A
3% discount rate was used for both costs and QALYs.
RESULTS: For predominantly classic AMD, Lucentis 0.5 mg
was a dominant strategy compared to PDT and the Incremental
Cost-Effectiveness Ratio (ICER) for Lucentis 0.5 mg relative to
Lucentis 0.3 mg was $62,905/QALY. For patients with mini-
mally classic or occult AMD, Lucentis 0.5 mg was a dominant
strategy compared to best supportive care and the ICER for
Lucentis 0.5 mg relative to Lucentis 0.3 mg was $322,367/
QALY. Inﬂuential variables driving the results in this analysis
include a patient’s baseline visual acuity, costs associated with
visual impairment, and the price of Lucentis. CONCLUSION:
Despite its high treatment costs, Lucentis is a dominant strategy
compared to PDT and best supportive care primarily because it
prevents patients from reaching the highly expensive state of
blindness. Treating AMD patients with Lucentis before they
reach a legal blindness state can generate considerable cost-
savings to society.
PSS16
A COST-EFFECTIVENESS ANALYSIS OFTWOTOPICAL
OPHTHALMIC ANTIBIOTIC SOLUTIONS INDICATED FOR
THETREATMENT OF BACTERIAL CONJUNCTIVITIS
Waycaster C
Alcon Laboratories Inc, Fort Worth,TX, USA
OBJECTIVE: The objective of this study was to compare the
cost-effectiveness of moxiﬂoxacin 5 mg/ml ophthalmic solution
(MF) to polymyxin B 10,000 units/trimethoprim 1mg/ml oph-
thalmic solution (PT) for the treatment of bacterial conjunctivitis
(BC). METHODS: Physician-assessed BC early clinical cure rates
were taken on day-2 of 7 day therapy from a multi-site, random-
ized, double-masked study comparing MF to PT. The clinical
cure rates were used to calculate a number-needed-to-treat
(NNT) estimate for the most efﬁcacious alternative. NNT was
then used as the measure of effect in an incremental cost-
effectiveness analysis. Only the direct costs of drug therapy were
considered in the economic analysis. The drug costs were derived
from a standard reference source. The economic perspective was
that of the payer. No cost discounting was performed due to the
short time horizon of BC therapy. RESULTS: Thirty-two subjects
(47 eyes) received MF and 30 subjects (43 eyes) received PT. At
baseline there were no statistical differences in BC severity or
duration, patient age, gender or ethnicity between the two treat-
ment groups. After 2 days of topical ophthalmic antibiotic
therapy, 83.3% of the MF patients were deemed clinically cured
compared to 43.2% of the PT patients. The NTT for the MF
group was estimated at 2.5. The MF incremental cost-
effectiveness ratio (ICER), the cost of curing one more BC patient
earlier, was estimated at $37.28. CONCLUSION: MF cures BC
sooner than PT thus reducing the duration of illness experienced
by BC patients. Since MF is a newer and more potent antibiotic
than PT, it incurs additional costs. The incremental cost to obtain
the additional beneﬁt of an earlier cure from MF therapy is
relatively small (< $0). Further research may demonstrate a lower
cost-effectiveness ratio from MF therapy if the indirect costs of
BC are considered.
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ECONOMIC EVALUATION OF MELOXICAM SOLUTION 0.030%
RESPECT AN OPHTHALMIC SODIUM DICLOFENAC
SOLUTION 0.1% ONTHE EYES OF PATIENTSWHO
UNDERWENTTO LASIK LASER EYE SURGERY AT
THE IMMEDIATELY POST-OPERATIVETIME
Baiza L
Sophia Pharmaceuticals, Guadalajara, Jalisco, Mexico
OBJECTIVE: Compare the effectiveness and costs of the admin-
istration of an ophthalmic Meloxicam solution 0.030% with a
sodium Diclofenac solution 0.1% on the eyes of patients who
underwent to Lasik laser eye surgery at the immediately post-
operative time. METHODS: Adopting the perspective of a health
care payer, we developed a cost-effectiveness analysis. Temporary
horizon was three months. A discounting rate was not used. The
source of information of cost and effectiveness was a randomized
clinical trial. The perspective was from Mexican Institute of
social Security. The method used for cost was microcosting and
case mix. The effectiveness was measured with different end
points. The cost-effectiveness analysis was made for those vari-
ables with statistically signiﬁcant differences. The evaluation was
made with incremental analysis and net beneﬁts approach. The
sensitivity analyses was of one way, two ways and probabilistic.
RESULTS: The highest cost was with Diclofenac solution
(USD$9.29) that was 5.9% higher than Meloxicam ($8.74) the
measured efﬁcacy named Flare and ciliary injection was superior
with Meloxicam compared with Diclofenac 148 vs. 149 for Flare
and 150 vs 153 respectively (p < 0.0001) for ciliary injection, the
cost for success obtained with Meloxicam was of USD$8.74 and
USD$9.29 with Diclofenac, the incremental analysis show that
Meloxicam is dominant over Diclofenac. Health Net Beneﬁts,
Monetary Net Beneﬁts and the Acceptability curves were favour-
able for Meloxicam independent the willingness to pay.
CONCLUSION: The Meloxicam solution was dominant over
Diclofenac in the application on the ocular surface in patients
who underwent to Lasik laser eye surgery in the immediate
postoperative period. The sensitivity analysis was a robust basis
for the study.
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INTHETREATMENT OF CHRONIC PLAQUE PSORIASIS:
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OBJECTIVE: It is the objective of this study to estimate the cost
per treatment success over a one-year timeframe of the ﬁve
biologic therapies used to treat patients with moderate to severe
psoriasis in the United States. METHODS: A Markov model was
developed to compare the relative cost components in psoriasis
treatment with biologics. Drug costs were based on wholesale
acquisition cost with consideration of net contractual discounts
and patient co-share or co-payment. Clinical efﬁcacy, for both
short-term (12 weeks) and longer-term (24+ weeks) treatment,
was based on the published peer-reviewed literature. The primary
economic endpoint was the cost of therapy (deﬁned as the cost of
drugs, laboratory, infusion, and professional services) per 75%
improvement from baseline in the Psoriasis Area and Severity
Index score (PASI 75) achieved. Analysis was conducted for each
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of the biologic agents currently utilized in the United States for
this indication (adalimumab, alefacept, efalizumab, etanercept
and inﬂiximab). Model results were displayed for a time horizon
of one year based on a switch to an appropriate alternate biologic
agent in the event of suboptimal clinical response. Multiple one-
way sensitivity analyses were conducted. RESULTS: Across all
the biologics evaluated there are signiﬁcant differences in PASI 75
response at 12 weeks versus longer term (ranging from 59% to
20% across the agents at the end of one quarter of treatment and
at the end of four quarters of treatment, respectively). The cost
per PASI 75 was observed to be $26,460, $31,191, $28,217,
$30,544 and $30,983 for therapy initiated with adalimumab,
alefacept, efalizumab, etanercept and inﬂiximab, respectively.
CONCLUSION: While there are signiﬁcant differences in the
cost of the studied biologic agents initially, the CE results tend to
converge over the ﬁrst year of treatment. Further research needs
to be conducted to evaluate the CE of treatment beyond a one-
year period.
PSS19
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DEGENERATION (AMD) IN MEXICO
Vega-Hernández GY1, Idrovo-Velandia J2, Rivas R3, Zapata L3,
Venegas J4, Ramírez H5, Mould-Quevedo J6, Davila-Loaiza G6
1Pﬁzer Mexico, DF, Mexico City, Mexico, 2Insituto Nacional de Salud
Pública, Cuernavaca, Morelos, Morelos, Mexico, 3Guia Mark, México,
DF, Mexico, 4Guiamark SC, Mexico City, Mexico, 5Guiamark SC,
Mexico City, Mexico City, Mexico, 6Pﬁzer Mexico, Mexico City, Mexico
OBJECTIVE: In western countries AMD is considered one of the
most important causes of blindness among persons over 65 years
old. The purpose of this study was to determine the cost-
effectiveness of pegaptanib vs verteporﬁn in the treatment of
AMD from the health care payer’s perspective. METHODS: A
seven-stage stochastic Markov model based on visual acuity (VA)
in the better seeing-eye (stages: with clinical beneﬁt, VA>20/40;
VA:20/40–20/; VA:20/100–20/160; VA:20/200–20/500; VA < 20/
500 and legal blindness) was performed during a ﬁve-year
period. Effectiveness measure used in the assessment was the
probability to gain at least one-level of VA at the end of the
follow up period. Effectiveness data was obtained from interna-
tional published literature. Comparators used in the model were
pegaptanib 0.3 mg (8 sessions) and verteporﬁn 15 mg (10 ses-
sions). Resource use and cost data were obtained from hospital
records and ofﬁcial institutional databases from the Social Secu-
rity Mexican Institute (IMSS). Costs and health outcomes were
discounted with a 3% annual rate. The model was calibrated.
Probabilistic sensitivity analyses were performed to determine
the results robustness. RESULTS: Patients who received pegap-
tanib experienced a higher probability to gain at least one level of
VA(57.4%; CI95%:52.26%–62.54%) compared with patients
treated with verteporﬁn (13.8%; IC95%:10.61%–16.99%) con-
sidering an initial VA state of “>20/40”(p < 0.001). Mean total
costs per patient were higher in patients who received pegaptanib
compared to those who received verteporﬁn (US$6749;
CI95%:US$6401–US$7096 vs. US$6311 CI95%:US$5948–
US$6674; respectively). The ICER in patients receiving pegap-
tanib compared to those receiving verteporﬁn was US$1004
(CI95% US$926–US$1090). Sensitivity analyses found that
pegaptanib is a cost-saving strategy when the numbers of sessions
given to the patients are less than three. CONCLUSION: The
results show that in Mexico, pegaptanib is a cost-effective
therapy for AMD when is compared with verteporﬁn. These
results should be taken into account by Mexican decision makers
in the management of patients with AMD.
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COST-EFFECTIVENESS OFTOBRADEXVERSUS ZYLET FOR
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OBJECTIVE: Blepharokeratoconjunctivitis (BKC) is a disease
characterized by inﬂammation of the eye lid, conjunctiva and
cornea and is typically treated empirically with topical antibiotic/
anti-inﬂammatory agents. The purpose of this study was to
compare the cost-effectiveness of tobramycin 0.3%/loteprednol
0.5%, (Zylet) to tobramycin 0.3%/dexamethasone 0.1%, (Tobra-
dex) for the rapid control of BKC. METHODS: Effectiveness
data for this analysis came from a randomized, double-masked,
parallel-group study of forty patients with BKC. Patients were
treatedwith eitherZylet™orTobradex®administered twice daily
in the test eye. Themeasure of effectiveness usedwas the change in
a clinical composite score of four BKC components: blepharitis,
ocular discharge, conjunctivitis, and corneal punctuate epithelial
keratopathy (PEK). Each clinical component was graded on a
scale of 0 (minimum) to three (extensive) and assessed at baseline
and on day 4 (1) of therapy. Five different pharmacy chains were
surveyed as to their prices for a 5ml bottle of both Tobradex and
Zylet. The average price of each agent was used as the cost
measure in the analysis. A probabilistic sensitivity analysis evalu-
ated the robustness of the economic outcomes. The economic
perspective was that of the payer. Due to the short time span
no cost discounting was performed. RESULTS: Reductions in
the BKC clinical composite scores at the day-4 assessment were
calculated at 4.5 (SD  1.7) versus 7.1 (SD  1.2) for the Zylet
and Tobradex groups, respectively. The average retail costs for
Zylet and Tobradex were $96.45 (SD  $5.26) and $71.75
(SD  $5.48) respectively. The cost-effectiveness ratios for Zylet
and Tobradex therapy were $21.43 and $10.10, respectively. The
cost-effectiveness results remained consistent using the probabi-
listic sensitivity distributions tested. CONCLUSION: Tobradex
economically dominated Zylet for the rapid control of BKC
because it was both less costly and more effective.
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COST OF ILLNESS OFWORK-RELATED CHRONIC HAND
ECZEMA IN GERMANY
Diepgen T1, Hieke K2
1University Hospital Heidelberg, Heidelberg, Germany, 2NEOS Health
(a COPERA company), Binningen, Switzerland
OBJECTIVE: InGermany, 26%of reported and 36% (= 8’460) of
conﬁrmed work-related diseases are skin-related, in over 90% of
these cases hands are affected. However, there is a lack on com-
prehensive information on costs associated with chronic hand
eczema (CHE). The objective of this study was to assess the direct
and indirect costs of CHE.METHODS:Data on 151 Patientswith
occupational skin diseases entering a special rehabilitation
program were assessed for the preceding 12 months. Data were
derived from patient records and direct patient information.
Descriptive analyses froma societal perspectivewas performed for
all patients and by physician-rated severity (severity group 1:
no/mild; group 2: moderate/severe). DGUV (German Statutory
Accident Insurance) was the payer for all patients. RESULTS:
Mean age was 44.9 years, 64.9% of patients were male. Total
mean annual costs amounted to €8.160 (95% CI: 6.395–9.925)
per patient. Indirect costs represented 75% of total costs,
in-patient-rehabilitation 14%. Each other factor (out-patient ser-
vices, diagnostics, drugs, complementary therapies, out-of-pocket
expenses) contributed < 3% to overall costs. Disease severity
inﬂuencedQoL signiﬁcantly (DLQI-score of severity group 1: 7.9,
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